688626 Xiangyu Medical
- 34.25
- -0.98-2.78%
Xiangyu Medical News
Xiangyu Medical (688626.SH): Cumulative expenditure of 75.3852 million yuan to repurchase 1.1% of the shares.
On ****, Gelonhui reported that Xiangyu Medical (688626.SH) has announced that as of May 31, 2024, the company has accumulated a total of 1,761,012 shares of the company through the Shanghai Stock Exchange trading system through centralized bidding trading, accounting for 1.1006% of the total shares, with a highest repurchase price of 52.19 yuan/share and a lowest price of 32.70 yuan/share. The total amount of funds paid was RMB 75,385,243.15 yuan (excluding transaction fees such as commission and transfer fees).
Express News | Xiangyu Healthcare: Shareholders plan to reduce their holdings by no more than 1.99% in total
Xiangyu Medical (688626.SH): A total cost of 75.385,000 yuan to buy back 1.1% of the shares
Gelonghui, May 7, 丨 Xiangyu Medical (688626.SH) announced that as of April 30, 2024, the company had repurchased a total of 1,761,012 shares of the company through centralized bidding transactions, accounting for 1.1006% of the company's total share capital of 160,000,000 shares. The highest price of the repurchase transaction was 52.19 yuan/share, the lowest price was 32.70 yuan/share, and the total amount of capital paid was RMB 75,385,243.15 (not including transaction fees and transfer fees).
Xiangyu Healthcare (688626): Industry-university-research innovation advantages highlight driving both revenue and profit growth
Event: The company released the 2023 annual report and the first quarter report of 2024. The company achieved operating income of 745 million yuan (+52.46%) in 2023; net profit to mother of 227 million yuan (+81.03%)
Express News | Xiangyu Healthcare: The “trade-in” program has been launched and will continue to thoroughly study national policies and actively seize this market opportunity
Guoxin Securities released a research report on April 25 stating that it gave Xiangyu Healthcare (688626.SH) a purchase rating. The main reasons for the rating include: 1) rapid growth in performance in 2023, strong recovery in demand for rehabilitation d
Guoxin Securities released a research report on April 25 stating that it gave Xiangyu Healthcare (688626.SH) a purchase rating. The main reasons for the rating include: 1) rapid growth in performance in 2023, strong recovery in demand for rehabilitation devices after the epidemic; 2) increased profitability and lower cost rates; 3) the first equity incentives after launch, demonstrating confidence in development. (Mainichi Keizai Shimbun)
Xiangyu Medical (688626): Net profit due to mother increased by 81% in 2023 and continued to increase R&D investment
Performance grew rapidly in 2023, and demand for rehabilitation devices recovered strongly after the pandemic. In 2023, the company achieved revenue of 745 million yuan (+52.46%), net profit attributable to mother of 227 million yuan (+81.03%), after deduction
Xiangyu MedicalLtd's (SHSE:688626) Performance Raises Some Questions
Investors were disappointed with Xiangyu Medical Co.,Ltd's (SHSE:688626) recent earnings release. We did some digging and found some underlying numbers that are worrying. SHSE:688626 Earnings and
Express News | Guohai Securities gave an initial rating to Xiang Yu Medical Buy.
Guohai Securities released a research report on April 23 stating that it gave Xiangyu Healthcare (688626.SH) a purchase rating. The main reasons for the rating include: 1) achieving relatively rapid growth in performance; 2) focusing on shareholder return
Guohai Securities released a research report on April 23 stating that it gave Xiangyu Healthcare (688626.SH) a purchase rating. The main reasons for the rating include: 1) achieving relatively rapid growth in performance; 2) focusing on shareholder returns and increasing dividends. (Mainichi Keizai Shimbun)
Xiangyu Medical (688626): R&D builds competitive advantage, and performance achieves rapid growth
Incident: Xiangyu Medical released the 2023 Annual Report and 2024 Quarterly Report on April 18: In 2023, the company achieved revenue of 745 million yuan (+52%, year-on-year scale, same below) and net profit of 2.27 million yuan to mother
Open Source Securities released a research report on April 19 stating that it gave Xiangyu Healthcare (688626.SH) a purchase rating. The main reasons for the rating include: 1) rapid growth in 2023 performance, outstanding market advantages for a full ran
Open Source Securities released a research report on April 19 stating that it gave Xiangyu Healthcare (688626.SH) a purchase rating. The main reasons for the rating include: 1) rapid growth in 2023 performance, outstanding market advantages for a full range of rehabilitation solutions, maintaining “buying” reviews; 2) the rehabilitation circuit is destined for long-term stable development in the context of accelerated aging, and rehabilitation leaders will benefit more and more; 3) 2024Q1 revenue achieved steady growth under a high base, laying a solid foundation for achieving annual revenue goals. (Mainichi Keizai Shimbun)
Does The Market Have A Low Tolerance For Xiangyu Medical Co.,Ltd's (SHSE:688626) Mixed Fundamentals?
With its stock down 23% over the past month, it is easy to disregard Xiangyu MedicalLtd (SHSE:688626). It seems that the market might have completely ignored the positive aspects of the company's fu
Xiangyu Healthcare (688626) 2023 Annual Report and 2024 Quarterly Report Review: Strong business recovery in 2023, equity incentives show confidence
Incident 1: The company released its 2023 annual report, achieving operating income, net profit attributable to mother, and net profit excluding non-return to mother of 745/2.27/ 204 million yuan respectively, +52%/81%/162% over the same period last year. Cash from operating activities
The brain-computer interface sector fluctuated and declined. Xiangyu Medical fell by more than 8%, while Aipon Healthcare, Unicharm, Yingqu Technology, Nanjing Panda, and Jiahe Intelligence followed suit.
The brain-computer interface sector fluctuated and declined. Xiangyu Medical fell by more than 8%, while Aipon Healthcare, Unicharm, Yingqu Technology, Nanjing Panda, and Jiahe Intelligence followed suit.
The medical device sector declined, and Xiangyu Medical fell more than 10%
Gelonghui, April 18 | Xiangyu Medical fell by more than 10%, followed by Beautiful Healthcare, Bohui Innovation, Aibang Healthcare, Lanwei Medical, and Yangpu Healthcare.
Xiangyu Healthcare (688626): Steady growth in performance, optimistic about high-end layout
Key investment performance results: On April 17, 2024, the company released the 2023 and 2024 quarterly reports. Specifically: 2023: Revenue of 740 million yuan, YOY 52.5%; net return to mother
Xiangyu Healthcare (688626.SH): Net profit of 39.07 million yuan in the first quarter increased 3.34% year-on-year
Gelonghui, April 17丨Xiangyu Medical (688626.SH) released its first quarter report. Operating revenue was 169 million yuan, up 18.12% year on year, net profit was 39.07 million yuan, up 3.34% year on year, after deducting non-net profit of 36.48 million yuan, up 12.07% year on year, with basic earnings of 0.25 yuan per share.
Xiangyu Medical (688626.SH) has spent 73.5532 million yuan to buy back 1.07% of the shares
Xiangyu Medical (688626.SH) issued an announcement. As of March 31, 2024, the company approved Shanghai Securities...
Express News | The ban on restricted shares with a market capitalization of 21.0838 billion yuan was lifted today, and Xiangyu Medical ranked first with a market capitalization of 4.802 billion yuan
Analysis
Price Target
No Data
